The Potential of HSP Inhibitors as Radiation Sensitizers
Laurie Gaspar, MD, from the University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
Currently, most of the research in this setting has been preclinical. Gaspar believes that this would be a promising area for HSP inhibitors, as they could be combined with a smaller dose of radiation, and consequently limit the side effects.
Clinical Pearls
Gaspar says that the radiation-sensitizing potential of HSP inhibitors could exist in any cell, but may work best in radiation-resistant cells. This could be the right time to move this theory into the clinical setting for lung cancer.
- There has been some preclinical research into using heat shock protein (HSP) inhibitors as a radiation sensitizer in lung cancer
- HSP inhibitors as a radiation sensitizer could lessen the dose, and the side effects, of radiation therapy
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
